Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antroquinonol in Atopic Dermatitis
NCT03622463Phase 2Completed
- Sponsor
- Golden Biotechnology Corporation
- Start
- Jul 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of antroquinonol in atopic dermatitis (AD) (3 arms), sponsored by Golden Biotechnology Corporation. Primary endpoint: Eczema Area and Severity Index at 12 weeks. Started Jul 2018; status: completed.
02
Drugs
antroquinonol
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03622463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622463.